Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Free Report) CEO John Treace bought 4,508 shares of Treace Medical Concepts stock in a transaction that occurred on Tuesday, May 26th. The stock was purchased at an average cost of $2.79 per share, for a total transaction of $12,577.32. Following the purchase, the chief executive officer owned 7,162,821 shares of the company’s stock, valued at $19,984,270.59. The trade was a 0.06% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Treace Medical Concepts Stock Performance
NASDAQ TMCI opened at $3.46 on Friday. The company has a quick ratio of 2.53, a current ratio of 3.58 and a debt-to-equity ratio of 0.72. The company has a 50-day simple moving average of $1.98 and a two-hundred day simple moving average of $2.25. The firm has a market cap of $224.45 million, a price-to-earnings ratio of -3.57 and a beta of 1.10. Treace Medical Concepts, Inc. has a 12-month low of $1.17 and a 12-month high of $7.78.
Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) last posted its earnings results on Friday, May 8th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. Treace Medical Concepts had a negative net margin of 29.44% and a negative return on equity of 67.04%. The company had revenue of $47.20 million during the quarter, compared to analyst estimates of $45.96 million. On average, equities analysts forecast that Treace Medical Concepts, Inc. will post -0.88 EPS for the current year.
Institutional Investors Weigh In On Treace Medical Concepts
Analyst Ratings Changes
A number of brokerages have weighed in on TMCI. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Treace Medical Concepts in a research note on Monday, April 20th. Wall Street Zen raised shares of Treace Medical Concepts from a “strong sell” rating to a “sell” rating in a research note on Monday, April 27th. Finally, Lake Street Capital decreased their target price on shares of Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating for the company in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $4.77.
View Our Latest Report on TMCI
About Treace Medical Concepts
Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.
The Lapiplasty System has received clearance from the U.S.
Read More
- Five stocks we like better than Treace Medical Concepts
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.
